Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial (PITA)

April 26, 2021 updated by: Lindsay Speros Robbins, MD, MPH, University of Alabama at Birmingham
Artificial rupture of membranes (amniotomy) is a commonly used technique to safely induce and augment labor. It has been shown to reduce the duration of spontaneous and induced labor in term patients (≥37 weeks' gestation). The utility of amniotomy in preterm patients (<37 weeks' gestation) undergoing medically-indicated induction of labor is unknown. However, it remains a commonly used strategy. We will conduct a trial comparing early amniotomy versus late amniotomy during medically-indicated induction of labor between 23.0 and 35.6 weeks gestation. Women will be randomized to early or late amniotomy after the obstetrician has decided to induce labor for a medical indication. We hypothesize that more women in the early amniotomy group will require cesarean delivery, and the duration of labor will increase in the early amniotomy group.

Study Overview

Detailed Description

The rate of preterm birth in the United States is nearly 10%. Up to one-third of these births are the result of a medically-indicated delivery. While induction of labor in women at term gestation has been extensively studied, the same is not true for preterm gestations. Consequently, the same methods of labor induction are used in term and preterm gestations, although preterm gestations may have different responses to induction agents compared to term gestations.

At our institution, a standard induction of labor - for term or preterm women - is performed using a cervical Foley catheter or misoprostol for cervical ripening with the addition of intravenous oxytocin for labor augmentation. As membranes do not typically spontaneously rupture during the induction process, amniotomy is commonly utilized by providers to help augment labor. Amniotomy releases prostaglandin-rich amniotic fluid. These prostaglandins are important mediators of uterine contractility and ultimately active labor. It has been shown to reduce the duration of spontaneous and induced labor in term patients.

The timing of amniotomy is left up to the discretion of the treating providers, as there are no randomized controlled trials to support early versus late amniotomy at preterm gestations. However, a retrospective cohort of nulliparous and multiparous women at our institution undergoing induction at 23-34 weeks, and evaluating early amniotomy at <4cm cervical dilation versus late amniotomy at ≥4cm dilation, showed an increased risk of cesarean delivery and increased time from start of induction to delivery for early amniotomy, although only the cesarean delivery outcome was significant after adjusting for confounders.

We will conduct an intention-to-treat randomized controlled trial comparing early amniotomy versus late amniotomy during medically-indicated induction of labor between 23.0 and 35.6 weeks gestation. Women will be randomized to early or late amniotomy after the attending obstetrician has decided to induce labor for a medical indication. Early amniotomy will be performed prior to 4cm cervical dilation being reached. Late amniotomy will be performed at greater than or equal to 4cm cervical dilation.

The purpose of this study is to determine whether timing of amniotomy during medically-indicated preterm induction of labor affects labor outcomes. We will specifically be looking at risk of cesarean delivery, duration of labor, maternal morbidity, and neonatal morbidity. We hypothesize that more women in the early amniotomy group will require cesarean delivery and that the duration of labor will increase in the early amniotomy group.

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35233
        • University of Alabama at Birmigham, Women and Infants' Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Singleton gestation
  • Gestational age at randomization between 23.0 and 35.6 weeks
  • Induction of labor planned for maternal or fetal indications
  • Reassuring fetal status
  • Vertex presentation

Exclusion Criteria:

  • Plan for cesarean delivery or contraindication to labor
  • Cervix ≥4cm dilated at start of induction
  • Signs of spontaneous labor (active contractions with cervical change)
  • Ruptured membranes
  • Chorioamnionitis
  • Intrauterine fetal demise
  • Known major fetal anomaly
  • Participation in any other clinical trial involving the course of labor
  • Maternal hepatitis B, C, or HIV infection (or unknown status)
  • Deferring intrapartum fetal monitoring and/or cesarean section for any reason (for example, after periviability counseling)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early amniotomy
Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
Experimental: Late amniotomy
Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cesarean delivery
Time Frame: Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.
Proportion of women requiring cesarean delivery
Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Interval from induction onset to delivery
Time Frame: Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.
Time (hours) from the start of induction (initiation of first cervical ripening agent) to delivery (vaginal or cesarean)
Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.
Interval from induction onset to vaginal delivery
Time Frame: Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.
Time (hours) from the start of induction (initiation of first cervical ripening agent) to vaginal delivery only
Duration is dependent upon the length of labor. The maximum time frame would be anticipated to be 120 hours from start of the induction.
Composite maternal morbidity
Time Frame: Measured from start of induction of labor up to 42 days following delivery

Composed of seven outcomes:

  1. chorioamnionitis (defined as maternal fever >100.3 plus maternal tachycardia, fetal tachycardia, purulent amniotic fluid, or fundal tenderness prior to delivery)
  2. endometritis (defined as maternal fever >100.3 at least 12 hours after delivery with fundal tenderness or purulent discharge)
  3. surgical site infection (infection within 30 days at the surgical site including superficial, deep, organ/space infections)
  4. pneumonia (radiologic diagnosis of pneumonia accompanied by clinical signs/symptoms)
  5. urinary tract infection (>100,000 colonies of a single species in urine culture accompanied by clinical signs/symptoms)
  6. postpartum hemorrhage (estimated blood loss >1000 mL)
  7. umbilical cord prolapse
Measured from start of induction of labor up to 42 days following delivery
Composite neonatal morbidity
Time Frame: Measured up to 28 days of life for the newborn

Composed of five outcomes:

  1. perinatal death (death of a fetus during labor or within 28 days of life)
  2. neonatal sepsis (critically ill infant in whom systemic infection is suspected with a positive blood, cerebrospinal fluid (CSF), or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection)
  3. intraventricular hemorrhage (confirmed on ultrasound or MRI)
  4. cord blood acidemia (umbilical artery gas pH <= 7.0 or base excess >= 12)
  5. Apgar <5 at 5 minutes
Measured up to 28 days of life for the newborn

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lindsay S Robbins, MD, MPH, University of Alabama at Birmingham

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2018

Primary Completion (Actual)

August 26, 2020

Study Completion (Actual)

January 13, 2021

Study Registration Dates

First Submitted

April 12, 2018

First Submitted That Met QC Criteria

April 12, 2018

First Posted (Actual)

April 20, 2018

Study Record Updates

Last Update Posted (Actual)

April 27, 2021

Last Update Submitted That Met QC Criteria

April 26, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Labor Induction

Clinical Trials on Early Amniotomy

3
Subscribe